Welcome to our dedicated page for NovaBridge Biosciences SEC filings (Ticker: NBP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NovaBridge Biosciences (NBP) SEC filings page on Stock Titan provides access to the company’s official disclosures as a foreign private issuer listed on Nasdaq. NovaBridge, formerly known as I-Mab, files reports such as Form 20-F and Form 6-K that describe its financial condition, risk factors, and operational progress as a global biotechnology platform company.
In these filings, NovaBridge outlines its business model, which combines business development and translational clinical development to advance a pipeline led by givastomig, ragistomig, uliledlimab, and VIS-101. Management’s discussion and analysis sections describe how the company allocates resources to oncology and ophthalmology programs, summarizes its collaborations with partners such as ABL Bio, and explains the structure of subsidiaries like Visara within its hub-and-spoke framework.
Investors reviewing NovaBridge’s SEC reports can examine clinical development disclosures for givastomig, including its positioning as a Claudin 18.2 x 4-1BB bispecific antibody in gastric and other gastrointestinal cancers, and for ragistomig as a PD-L1 x 4-1BB bispecific in solid tumors. Filings also discuss rights to uliledlimab outside Greater China and the VIS-101 license and assignment arrangements involving Visara and Everest Medicines.
Stock Titan enhances these regulatory documents with AI-powered summaries that highlight key points from lengthy filings, helping readers quickly understand topics such as segment descriptions, collaboration agreements, share incentive plans, and subsequent events. Users can follow new 6-K submissions for interim updates, and consult annual filings for a more comprehensive view of NovaBridge’s strategy, risk profile, and pipeline.
By using this page, investors and researchers can monitor NovaBridge’s official SEC communications in real time, while AI-generated insights help interpret complex biotech and capital markets information contained in the original documents.
NovaBridge Biosciences executive Xu Cong Claire filed an amended Form 3 to correct a typographical error in her reported holdings. She is now shown as beneficially owning 284,266 Ordinary Shares, which are represented by 123,594 American Depositary Shares (ADSs). Each 10 ADSs correspond to 23 Ordinary Shares. The amendment states that all other information from the original Form 3 remains unchanged and does not report any new share purchases, sales, or option exercises.
NovaBridge Biosciences reported a larger full-year 2025 loss while strengthening its balance sheet and advancing two lead drug programs. The company posted a net loss attributable to NovaBridge of $46.3 million from continuing operations, compared with $22.2 million in 2024, as research and development spending more than doubled to $62.9 million, driven mainly by in‑process R&D for VIS‑101 and the Bridge Health acquisition. Administrative expenses were $31.4 million, slightly higher year over year.
Cash, cash equivalents and short‑term investments reached $210.8 million as of December 31, 2025, aided by a $61.7 million underwritten equity offering, and are expected to fund operations through 2028. The pipeline is led by givastomig, a Claudin 18.2 × 4‑1BB bispecific antibody for first‑line gastric cancer, which showed a 75% objective response rate and 16.9‑month median progression‑free survival in Phase 1b, and has potential eligibility for the FDA’s Accelerated Approval Pathway with a registrational Phase 3 trial targeted as early as late 2026. VIS‑101, a VEGF‑A × ANG‑2 inhibitor for wet age‑related macular degeneration, delivered rapid, durable responses in Phase 2a with roughly half of treatment‑naïve patients remaining retreatment‑free at six months, and is planned to enter Phase 2b in the second half of 2026.
NovaBridge Biosciences, a Cayman Islands holding company focused on precision immuno-oncology and ophthalmology, reports that it had 265,377,891 ordinary shares outstanding as of December 31, 2025. The company divested its Greater China assets in April 2024 for contingent consideration of up to $80 million tied to future milestones and royalties, and now operates primarily through U.S. and limited PRC subsidiaries.
NovaBridge remains a clinical-stage company with no approved products and recorded net losses of $88.3 million in 2025. It held $210.8 million in cash, cash equivalents and short-term investments, which it believes will fund operations into the fourth quarter of 2028. Management highlights reliance on additional financing, complex PRC regulatory risks, HFCAA-related audit considerations, material weaknesses in IT general controls and a 27% workforce reduction under a 2025 realignment plan as key risk factors for investors.
NovaBridge Biosciences director Yang Conor Chia-hung filed an initial ownership report showing two employee stock option positions tied to the company’s Ordinary Shares. One 2024 option covers 114,093 underlying Ordinary Shares at an exercise price of $1.22 per ADS-equivalent, expiring on October 1, 2034, and is fully vested and exercisable. A 2025 option covers 34,530 underlying Ordinary Shares at an exercise price of $3.86 per ADS-equivalent, expiring on October 1, 2035, and will vest in full on the first anniversary of its October 1, 2025 grant date. Footnotes note that the Ordinary Shares may be represented by ADSs, with each 10 ADSs representing 23 Ordinary Shares.
NovaBridge Biosciences officer Chu Denny Hsueh Wen filed a Form 3 as an officer of the company. The filing lists no reportable transactions, with buy, sell, acquire, dispose, exercise, gift, tax withholding, and restructuring counts all shown as zero in this excerpt.
NovaBridge Biosciences Chief Medical Officer Dennis Phillip Andrew filed an initial ownership report, listing his equity awards and share holdings. He holds 2024 employee share options over 494,510 underlying Ordinary Shares at an exercise price of 1.8200 and additional options over 186,300 underlying Ordinary Shares at 1.0500, both expiring in 2034. He also holds 92,724 restricted share units tied to Ordinary Shares and 142,740 Ordinary Shares directly. The footnotes explain that the securities may be represented by ADSs and that the options and RSUs vest over four years under specified schedules.
NovaBridge Biosciences General Counsel Lin Liwei Lorraine has filed an initial statement of beneficial ownership on Form 3 as an officer of the company. The filing identifies her role as General Counsel but does not list any stock purchases, sales, or other transactions.
NovaBridge Biosciences director and officer Fu Xi-Yong has filed an initial ownership report detailing equity interests in the company. The filing lists 2025 employee share options tied to 1,245,000 ordinary shares, with an exercise price of 1.07 per ADS and an expiration date of 2034-10-30. These options were granted on November 1, 2024 and vest in four equal annual installments starting on the first anniversary of the grant date.
The report also shows restricted share units linked to 1,245,000 underlying ordinary shares, each RSU representing a contingent right to receive one ADS that vests in four installments if the ADS achieves specified price targets. In addition, Fu Xi-Yong directly holds 59,823 ordinary shares, represented by 26,010 ADSs. Each 10 ADSs represent 23 ordinary shares of NovaBridge Biosciences.
NovaBridge Biosciences Chief Investment Officer reports initial ownership position. Zhang Xiaofan Neo reports beneficial ownership of 874,000 Ordinary Shares of NovaBridge Biosciences. According to the footnotes, these reported securities are represented by 380,000 American Depositary Shares, where each 10 ADSs represent 23 Ordinary Shares.
NovaBridge Biosciences disclosed initial insider holdings for its Chief Financial Officer, Lei Ming Kyler, through a 2025 Employee Share Option award. The option covers 996,775 underlying securities at an exercise price of 4.25 per ADS and expires on October 16, 2035.
According to the footnotes, the option was granted on October 16, 2025 and vests over five years, with 40% vesting on the second anniversary of the grant date and the remainder vesting in equal portions on each following anniversary. The filing reflects existing option holdings rather than a new market purchase or sale.